The glucagon-like peptide-1 receptor (GLP-1R) market experienced significant growth in 2023, generating $37.2 billion in sales, with Denmark’s Novo Nordisk (NOV: N) and US major Eli Lilly (NYSE: LLY) dominating the sector.
However, emerging biotech companies are poised to disrupt this landscape, with promising pipeline products expected to generate substantial revenue and challenge the market leaders by 2030, says pharma analytics company GlobalData.
Currently, there are 323 active GLP-1Rs in the pipeline, with several estimated to deliver significant returns upon launch. While mega-cap companies dominate the GLP-1R market and are expected to maintain their stronghold in 2030, three smaller biotechs - Viking Therapeutics (Nasdaq: VKTX), Altimmune (Nasdaq: ALT), and Structure Therapeutics (Nasdaq: GPCR) - are emerging as potential disruptors in this drug category, giving hope to innovative newcomers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze